Amylyx will present the trial design of its Phase 3 ALS study (A35-004 PHOENIX) of AMX0035 at the European Network to Cure ALS (ENCALS) Meeting 2021.
Trial News & Events
The ALS Team at the Healey Center at Mass General Hospital is committed to an ongoing dialogue about the HEALEY ALS Platform Trial with the entire ALS patient community.
Please join us on Tuesday, September 29th at 5:00 pm EST for an update on the HEALEY ALS Platform Trial and remarks from Kuldip Dave of the ALS Association.
Nominations are now being accepted for the 2020 Virtual Clinical Research Learning Institute!
As the first ever platform trial for amyotrophic lateral sclerosis (ALS), the HEALEY ALS Platform Trial is testing three proposed drug regimens and will add two more over the next several months.
NEALS is pleased to announce a half-day training session for investigators interested in participating in ALS research as a Site Investigator in a multi-center clinical trial.
The NEALS ALS GAP (ALS Genetic Access Program) provides clinical genetics services to pALS who are under the care of a registered NEALS clinician.
As the COVID-19 situation continues to evolve, we know it is of particular concern for the ALS community, both for clinical care and research trials.
NEALS is pleased to announce a full day training session for investigators interested in developing and conducting multi-center ALS clinical trials as Principal Investigators.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the inaugural annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS.